Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Teva Could Face Damages Of $1.2 Billion For At-Risk Launch Of Generic Protonix

This article was originally published in The Pink Sheet Daily

Executive Summary

A jury finds that Pfizer's patent on the proton pump inhibitor is valid; analyst Timothy Anderson estimates that without a settlement Teva's damages could top $1 billion but thinks the actual impact will be smaller.

You may also be interested in...



Protonix Settlement Leaves Question Of How Jury Would Assess At-Risk Launch Damages

Teva and India’s Sun Pharma are to pay $2.15 billion for their at-risk launch in the U.S. of generic versions of Pfizer’s Protonix; Pfizer says figure represents lost profits and lost royalties from the three years the product faced premature generic competition.

Protonix Settlement Leaves Question Of How Jury Would Assess At-Risk Launch Damages

Teva and Sun are to pay $2.15 billion for their at-risk launch of generic versions of Pfizer’s Protonix; Pfizer says figure represents lost profits and lost royalties from the three years the product faced premature generic competition.

AstraZeneca, Korea’s Hanmi Move To Appellate Court In Nexium Patent Dispute

A recent settlement agreement at the U.S. district court level does little to resolve a battle over AstraZeneca’s second best-selling drug. Hanmi says its position is on “solid ground,” but it remains unclear if it would pursue an at-risk launch if it receives final FDA approval.

Related Content

Topics

UsernamePublicRestriction

Register

PS142351

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel